The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Medical Autologous Biologics Market Research Report 2025
Synopsis
Medical autologous biologics are therapeutic products derived from a patient's own cells, tissues, or blood components. The term "autologous" refers to the fact that the source of the biologic material is the individual receiving the treatment. These biologics are personalized medicines, custom-made for each patient, which helps reduce the risk of immune rejection and other complications commonly associated with allogeneic (donor-derived) therapies.
Global Medical Autologous Biologics market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Medical Autologous Biologics market research.
The global market for medical autologous biologics has been experiencing significant growth due to the increasing demand for personalized and regenerative therapies. Autologous biologics offer the advantage of being derived from a patient's own cells, reducing the risk of immune rejection and adverse reactions. They have found applications in various medical fields, including oncology, orthopedics, cardiovascular diseases, and wound healing. North America, with its well-established healthcare infrastructure and research capabilities, has been a major player in the medical autologous biologics market. European countries have shown increasing interest in regenerative medicine and personalized therapies, driving the adoption of medical autologous biologics. The Asia-Pacific region has seen a surge in research activities and clinical trials focused on autologous biologics, with countries like Japan, China, and South Korea being at the forefront.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Medical Autologous Biologics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Vericel Corporation
BioTime
Pharmicell
BrainStorm Cell Therapeutics
Opexa Therapeutics
Sartorius
Neostem
Dendreon Corporation
Regenexx
Cytori Therapeutics
Segment by Type
Adipose Tissue
Plasma
Others
Segment by Application
Hospitals
Research Center
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Medical Autologous Biologics report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Medical autologous biologics are therapeutic products derived from a patient's own cells, tissues, or blood components. The term "autologous" refers to the fact that the source of the biologic material is the individual receiving the treatment. These biologics are personalized medicines, custom-made for each patient, which helps reduce the risk of immune rejection and other complications commonly associated with allogeneic (donor-derived) therapies.
Global Medical Autologous Biologics market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Medical Autologous Biologics market research.
The global market for medical autologous biologics has been experiencing significant growth due to the increasing demand for personalized and regenerative therapies. Autologous biologics offer the advantage of being derived from a patient's own cells, reducing the risk of immune rejection and adverse reactions. They have found applications in various medical fields, including oncology, orthopedics, cardiovascular diseases, and wound healing. North America, with its well-established healthcare infrastructure and research capabilities, has been a major player in the medical autologous biologics market. European countries have shown increasing interest in regenerative medicine and personalized therapies, driving the adoption of medical autologous biologics. The Asia-Pacific region has seen a surge in research activities and clinical trials focused on autologous biologics, with countries like Japan, China, and South Korea being at the forefront.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Medical Autologous Biologics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Vericel Corporation
BioTime
Pharmicell
BrainStorm Cell Therapeutics
Opexa Therapeutics
Sartorius
Neostem
Dendreon Corporation
Regenexx
Cytori Therapeutics
Segment by Type
Adipose Tissue
Plasma
Others
Segment by Application
Hospitals
Research Center
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Medical Autologous Biologics report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Medical Autologous Biologics Market Overview
1.1 Product Overview and Scope of Medical Autologous Biologics
1.2 Medical Autologous Biologics Segment by Type
1.2.1 Global Medical Autologous Biologics Market Value Comparison by Type (2023-2029)
1.2.2 Adipose Tissue
1.2.3 Plasma
1.2.4 Others
1.3 Medical Autologous Biologics Segment by Application
1.3.1 Global Medical Autologous Biologics Market Value by Application: (2023-2029)
1.3.2 Hospitals
1.3.3 Research Center
1.3.4 Others
1.4 Global Medical Autologous Biologics Market Size Estimates and Forecasts
1.4.1 Global Medical Autologous Biologics Revenue 2018-2029
1.4.2 Global Medical Autologous Biologics Sales 2018-2029
1.4.3 Global Medical Autologous Biologics Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Medical Autologous Biologics Market Competition by Manufacturers
2.1 Global Medical Autologous Biologics Sales Market Share by Manufacturers (2018-2023)
2.2 Global Medical Autologous Biologics Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Medical Autologous Biologics Average Price by Manufacturers (2018-2023)
2.4 Global Medical Autologous Biologics Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Medical Autologous Biologics, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Medical Autologous Biologics, Product Type & Application
2.7 Medical Autologous Biologics Market Competitive Situation and Trends
2.7.1 Medical Autologous Biologics Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Medical Autologous Biologics Players Market Share by Revenue
2.7.3 Global Medical Autologous Biologics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Medical Autologous Biologics Retrospective Market Scenario by Region
3.1 Global Medical Autologous Biologics Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Medical Autologous Biologics Global Medical Autologous Biologics Sales by Region: 2018-2029
3.2.1 Global Medical Autologous Biologics Sales by Region: 2018-2023
3.2.2 Global Medical Autologous Biologics Sales by Region: 2024-2029
3.3 Global Medical Autologous Biologics Global Medical Autologous Biologics Revenue by Region: 2018-2029
3.3.1 Global Medical Autologous Biologics Revenue by Region: 2018-2023
3.3.2 Global Medical Autologous Biologics Revenue by Region: 2024-2029
3.4 North America Medical Autologous Biologics Market Facts & Figures by Country
3.4.1 North America Medical Autologous Biologics Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Medical Autologous Biologics Sales by Country (2018-2029)
3.4.3 North America Medical Autologous Biologics Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Medical Autologous Biologics Market Facts & Figures by Country
3.5.1 Europe Medical Autologous Biologics Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Medical Autologous Biologics Sales by Country (2018-2029)
3.5.3 Europe Medical Autologous Biologics Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Medical Autologous Biologics Market Facts & Figures by Country
3.6.1 Asia Pacific Medical Autologous Biologics Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Medical Autologous Biologics Sales by Country (2018-2029)
3.6.3 Asia Pacific Medical Autologous Biologics Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Medical Autologous Biologics Market Facts & Figures by Country
3.7.1 Latin America Medical Autologous Biologics Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Medical Autologous Biologics Sales by Country (2018-2029)
3.7.3 Latin America Medical Autologous Biologics Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Medical Autologous Biologics Market Facts & Figures by Country
3.8.1 Middle East and Africa Medical Autologous Biologics Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Medical Autologous Biologics Sales by Country (2018-2029)
3.8.3 Middle East and Africa Medical Autologous Biologics Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Medical Autologous Biologics Sales by Type (2018-2029)
4.1.1 Global Medical Autologous Biologics Sales by Type (2018-2023)
4.1.2 Global Medical Autologous Biologics Sales by Type (2024-2029)
4.1.3 Global Medical Autologous Biologics Sales Market Share by Type (2018-2029)
4.2 Global Medical Autologous Biologics Revenue by Type (2018-2029)
4.2.1 Global Medical Autologous Biologics Revenue by Type (2018-2023)
4.2.2 Global Medical Autologous Biologics Revenue by Type (2024-2029)
4.2.3 Global Medical Autologous Biologics Revenue Market Share by Type (2018-2029)
4.3 Global Medical Autologous Biologics Price by Type (2018-2029)
5 Segment by Application
5.1 Global Medical Autologous Biologics Sales by Application (2018-2029)
5.1.1 Global Medical Autologous Biologics Sales by Application (2018-2023)
5.1.2 Global Medical Autologous Biologics Sales by Application (2024-2029)
5.1.3 Global Medical Autologous Biologics Sales Market Share by Application (2018-2029)
5.2 Global Medical Autologous Biologics Revenue by Application (2018-2029)
5.2.1 Global Medical Autologous Biologics Revenue by Application (2018-2023)
5.2.2 Global Medical Autologous Biologics Revenue by Application (2024-2029)
5.2.3 Global Medical Autologous Biologics Revenue Market Share by Application (2018-2029)
5.3 Global Medical Autologous Biologics Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Vericel Corporation
6.1.1 Vericel Corporation Corporation Information
6.1.2 Vericel Corporation Description and Business Overview
6.1.3 Vericel Corporation Medical Autologous Biologics Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Vericel Corporation Medical Autologous Biologics Product Portfolio
6.1.5 Vericel Corporation Recent Developments/Updates
6.2 BioTime
6.2.1 BioTime Corporation Information
6.2.2 BioTime Description and Business Overview
6.2.3 BioTime Medical Autologous Biologics Sales, Revenue and Gross Margin (2018-2023)
6.2.4 BioTime Medical Autologous Biologics Product Portfolio
6.2.5 BioTime Recent Developments/Updates
6.3 Pharmicell
6.3.1 Pharmicell Corporation Information
6.3.2 Pharmicell Description and Business Overview
6.3.3 Pharmicell Medical Autologous Biologics Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Pharmicell Medical Autologous Biologics Product Portfolio
6.3.5 Pharmicell Recent Developments/Updates
6.4 BrainStorm Cell Therapeutics
6.4.1 BrainStorm Cell Therapeutics Corporation Information
6.4.2 BrainStorm Cell Therapeutics Description and Business Overview
6.4.3 BrainStorm Cell Therapeutics Medical Autologous Biologics Sales, Revenue and Gross Margin (2018-2023)
6.4.4 BrainStorm Cell Therapeutics Medical Autologous Biologics Product Portfolio
6.4.5 BrainStorm Cell Therapeutics Recent Developments/Updates
6.5 Opexa Therapeutics
6.5.1 Opexa Therapeutics Corporation Information
6.5.2 Opexa Therapeutics Description and Business Overview
6.5.3 Opexa Therapeutics Medical Autologous Biologics Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Opexa Therapeutics Medical Autologous Biologics Product Portfolio
6.5.5 Opexa Therapeutics Recent Developments/Updates
6.6 Sartorius
6.6.1 Sartorius Corporation Information
6.6.2 Sartorius Description and Business Overview
6.6.3 Sartorius Medical Autologous Biologics Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Sartorius Medical Autologous Biologics Product Portfolio
6.6.5 Sartorius Recent Developments/Updates
6.7 Neostem
6.6.1 Neostem Corporation Information
6.6.2 Neostem Description and Business Overview
6.6.3 Neostem Medical Autologous Biologics Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Neostem Medical Autologous Biologics Product Portfolio
6.7.5 Neostem Recent Developments/Updates
6.8 Dendreon Corporation
6.8.1 Dendreon Corporation Corporation Information
6.8.2 Dendreon Corporation Description and Business Overview
6.8.3 Dendreon Corporation Medical Autologous Biologics Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Dendreon Corporation Medical Autologous Biologics Product Portfolio
6.8.5 Dendreon Corporation Recent Developments/Updates
6.9 Regenexx
6.9.1 Regenexx Corporation Information
6.9.2 Regenexx Description and Business Overview
6.9.3 Regenexx Medical Autologous Biologics Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Regenexx Medical Autologous Biologics Product Portfolio
6.9.5 Regenexx Recent Developments/Updates
6.10 Cytori Therapeutics
6.10.1 Cytori Therapeutics Corporation Information
6.10.2 Cytori Therapeutics Description and Business Overview
6.10.3 Cytori Therapeutics Medical Autologous Biologics Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Cytori Therapeutics Medical Autologous Biologics Product Portfolio
6.10.5 Cytori Therapeutics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Medical Autologous Biologics Industry Chain Analysis
7.2 Medical Autologous Biologics Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Medical Autologous Biologics Production Mode & Process
7.4 Medical Autologous Biologics Sales and Marketing
7.4.1 Medical Autologous Biologics Sales Channels
7.4.2 Medical Autologous Biologics Distributors
7.5 Medical Autologous Biologics Customers
8 Medical Autologous Biologics Market Dynamics
8.1 Medical Autologous Biologics Industry Trends
8.2 Medical Autologous Biologics Market Drivers
8.3 Medical Autologous Biologics Market Challenges
8.4 Medical Autologous Biologics Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
